Azacitidine

Generic Name
Azacitidine
Brand Names
Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
Drug Type
Small Molecule
Chemical Formula
C8H12N4O5
CAS Number
320-67-2
Unique Ingredient Identifier
M801H13NRU
Background

Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...

Indication

Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...

Associated Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
Associated Therapies
-
Clinical Trials
Related News

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

Phase 2
Recruiting
Conditions
AML, Adult
Interventions
Drug: Selinexor
Drug: Azacitidine
Drug: Venetoclax
First Posted Date
2023-02-21
Last Posted Date
2023-03-15
Lead Sponsor
Shanghai Tong Ren Hospital
Target Recruit Count
58
Registration Number
NCT05736965
Locations
🇨🇳

Jilin University China Japan Union Hospital, Ch'ang-ch'un, China

🇨🇳

Changzhou Municipal No.1 People's Hospital, Changzhou, China

🇨🇳

Sichuan Provincial People's Hospital, Chengdu, China

and more 16 locations

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

First Posted Date
2023-02-09
Last Posted Date
2024-03-08
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT05720988
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

🇺🇸

Habtemariam,Bruck, Los Angeles, California, United States

AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

First Posted Date
2023-01-10
Last Posted Date
2023-01-10
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
200
Registration Number
NCT05678933
Locations
🇨🇳

Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China

A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

First Posted Date
2022-12-07
Last Posted Date
2024-02-02
Lead Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Target Recruit Count
198
Registration Number
NCT05641259
Locations
🇨🇳

The First Affiliated Hospital of Nanchang University, Nanchang, China

🇨🇳

First Affiliated Hospital of Soochow University, Suzhou, China

🇨🇳

Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment

First Posted Date
2022-11-28
Last Posted Date
2024-07-03
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
184
Registration Number
NCT05628623

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

Phase 1
Recruiting
Conditions
Advanced Systemic Mastocytosis
Interventions
Drug: BLU-263
Drug: Azacitidine
First Posted Date
2022-11-08
Last Posted Date
2024-04-02
Lead Sponsor
Blueprint Medicines Corporation
Target Recruit Count
67
Registration Number
NCT05609942
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇩🇪

University Medical Centre Mannheim, Mannheim, Germany

🇺🇸

Stanford Cancer Institute, Palo Alto, California, United States

and more 8 locations

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

First Posted Date
2022-10-19
Last Posted Date
2023-03-23
Lead Sponsor
Sunshine Lake Pharma Co., Ltd.
Target Recruit Count
324
Registration Number
NCT05586074
Locations
🇨🇳

the First Affiliated Hospital,College of Medicine,Zhejiang University, Hanzhou, China

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

First Posted Date
2022-10-04
Last Posted Date
2024-11-19
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
92
Registration Number
NCT05566054
Locations
🇨🇳

The First Affliated Hospital of Soochow University, Suzhou, Jiangsu, China

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

First Posted Date
2022-10-03
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
2000
Registration Number
NCT05564390
Locations
🇺🇸

Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States

🇺🇸

Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, United States

🇺🇸

Marshfield Medical Center - Weston, Weston, Wisconsin, United States

and more 184 locations

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

First Posted Date
2022-09-26
Last Posted Date
2024-07-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
184
Registration Number
NCT05554419
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy